Mathieu Blery

This inventor holds 14 USPTO granted patents and 10 published patent applications, plus 4 CIPO patents and 10 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Innate Pharma, Innate Pharma, S.a., Bristol-Myers Squibb Compnay. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mathieu Blery. Retrieved from https://idiyas.com/inventor/mathieu-blery

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 10)

% Patents Active = 92.9

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 10 (Patent Applications = 16)

Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 70(Granted Patents)

Company Filing History:

Bristol-Myers Squibb Compnay

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

Areas of Expertise:

NKp46 Binding Agents

Anti-NKG2A Antibodies

Peripheral T Cell Lymphoma

Inhibitory Pathways

Proliferative Disorders

Combination Therapies

Anti-KIR Antibodies

Anti-CS1 Antibodies

Cancer Treatments

Lymphocytes

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12365731 - NKp46 binding agents (2025-07-22),

2. 12037392 - Treatment regimens using anti-NKG2A antibodies (2024-07-16),

3. 11999784 - Treatment of peripheral T cell lymphoma (2024-06-04),

4. 11572410 - Neutralization of inhibitory pathways in lymphocytes (2023-02-07),

5. 11377492 - NKp46 binding agents (2022-07-05),

6. 11225519 - Treatment of cancers using anti-NKG2A agents (2022-01-18),

7. 10870700 - Neutralization of inhibitory pathways in lymphocytes (2020-12-22),

8. 10711063 - Neutralization of inhibitory pathways in lymphocytes (2020-07-14),

9. 10676523 - Treatment regimens using anti-NKG2A antibodies (2020-06-09),

10. 10577416 - Mica binding agents (2020-03-03),

11. 10494433 - Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma (2019-12-03),

12. 10344087 - Treatment of peripheral T cell lymphoma (2019-07-09),

13. 10329348 - Treatment of cancers using anti-NKG2A agents (2019-06-25),

14. 9447185 - Compositions and methods for treating proliferative disorders (2016-09-20),

Title: The Innovative Contributions of Mathieu Blery

Introduction

Mathieu Blery is a prominent inventor based in Marseilles, France. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents targeting cancer. With a total of 14 patents to his name, Blery's work has the potential to impact the treatment of various diseases.

Latest Patents

Among his latest patents, Blery has developed NKp46 binding agents. This invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. These proteins exhibit increased activity in treating disorders characterized by NKp46-expressing cells, particularly tumor cells. Another notable patent involves treatment regimens using anti-NKG2A antibodies. This invention relates to methods for treating diseases, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. The therapeutic regimens outlined in this patent aim to improve the efficacy of anti-NKG2A antibodies.

Career Highlights

Throughout his career, Mathieu Blery has worked with notable companies in the biotechnology sector, including Innate Pharma. His innovative work has positioned him as a key figure in the development of new cancer therapies.

Collaborations

Blery has collaborated with esteemed colleagues such as Pascale Andre and Carine Paturel. These partnerships have further enhanced his research and development efforts in the field.

Conclusion

Mathieu Blery's contributions to biotechnology and cancer treatment through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic strategies against cancer.

Profile summary based on public USPTO records.